Transgene Sa · EURONEXT:TNG
Transgene Sa — Investor Presentation (June 2025)
27 slides from Transgene Sa's investor presentation, Jun 1, 2025
Slide 1: Unlocking the Full Potential of the Immune System Against Cancer
Unlocking the Full Potential of the Immune System Against Cancer Investor Presentation June 1, 2025
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. There can be no guarantee that (i) the results of pre-clinical work and prior clinical trials will be
Slide 3: Transgene in a Snapshot
Transgene in a Snapshot Click to edit Master title style Lead program TG4050 Additional programs Unique and highly to deliver data and R&I activity to potent and create significant deliver news flow and viral vector-based value in early setting fuel Transgene’s immunotherapies solid tumors between p
Slide 4: myvac® – A Novel Individualized Cancer Immunotherapy Platform
myvac® – A Novel Individualized Cancer Immunotherapy Platform Click to edit Master title style MVA VIRAL VECTOR + THE RIGHT NEOANTIGENS INDICATION Induces broad and neoantigen- Comprises up to 30 neoantigens Targeting head and neck patients – specific immune response selected using NEC’s artificial
Slide 5: Innovative Clinical-Stage Immunotherapy Portfolio Based on Viral Vectors
Innovative Clinical-Stage Immunotherapy Portfolio Based on Viral Vectors Click to edit Master Product title style Indication Collaboration Discovery Phase I Phase II LEAD ASSET: INDIVIDUALIZED NEOANTIGEN CANCER VACCINES (myvac® platform) Phase I (n = 32) - No relapse in treatment arm with at least 2
Slide 6: Neoantigen Therapeutic Cancer Vaccine
Neoantigen Therapeutic Cancer Vaccine Focused on delivering the promise of individualized cancer vaccine
Slide 7: myvac® - TG4050 | Combines Unique Know How and Expertise
myvac® - TG4050 | Combines Unique Know How and Expertise Click to edit Master title style MVA viral vector: a powerful Clinically-validated Artificial Intelligence & platform for vaccine development Bioinformatics powered approach Neoantigen identification Strongly immunogenic vector • Based on mult
Slide 8: TG4050 | Operable Head and Neck Cancer - Trial after Surgery and Adjuvant Therapy
TG4050 | Operable Head and Neck Cancer - Trial after Surgery and Adjuvant Therapy Click to edit Master title style Need to prevent or delay relapse Phase I/II trial design Approx. 80 patients With currently approved treatments, with locoregionally advanced HPV-negative approx. 25% patients relapse S
Slide 9: TG4050 | Phase I Data – Compelling Data in High-Risk Patient Population
TG4050 | Phase I Data – Compelling Data in High-Risk Patient Population Click to edit Master title style Arm A Arm B Arm A Arm B Patient Characteristics (N=17*) (N=16) Pathological Risk Factors (N=17*) (N=16) TG4050 single agent Watchful waiting TG4050 single agent Watchful waiting Male / Female, n
Slide 10: TG4050 | Phase I Data – 100% DFS 2 Years after Treatment Initiation
TG4050 | Phase I Data – 100% DFS 2 Years after Treatment Initiation Clinical Proof Click to edit Masterof titlePrinciple style in Adjuvant Setting 2-year disease-free survival (DFS) All 16 treated patients remained disease-free 100% Median follow-up 81% of 30 months 3 patients in arm B TG4050 monoth
Slide 11: TG4050 | Phase I Data – Persistent Specific Cellular Response Following Vaccination
TG4050 | Phase I Data – Persistent Specific Cellular Response Following Vaccination Click to edit Master title style CD8 T cell responses persist over one year after the end of treatment (M24) Arm A Patients displayed sustained neoantigen- TG4050 single agent specific CD8+ responses against multiple
Slide 12: TG4050 | Potential to Extend Remission Period and Address Significant Medical Need
TG4050 | Potential to Extend Remission Period and Address Significant Medical Need Click to edit Master title style Head & Neck program one patient • one genome • one vaccine Positive Phase I part – 100% 24-month DFS Ongoing Phase II part – Last patient to be Signs Excellent of clinical safety rando
Slide 13: Other Viral Vector-Based Assets
Other Viral Vector-Based Assets Rapidly Generating Multiple Virus-Powered Off-the-Shelf Drug Candidates Targeting Solid Tumors
Slide 14: Our Oncolytic Viruses (OV) – Combined Effects of Vector, Payload and Immune Stimulation
Our Oncolytic Viruses (OV) – Combined Effects of Vector, Payload and Immune Stimulation Compelling Clinical Click to edit Master Data Support Intravenous (IV) Route of Administration title style Patented Backbone VVcopTK-RR- vector with multiple competitive advantages: Cancer cell death through mult
Slide 15: BT-001 | Promising Antitumor Activity of OV Armed with Anti-CTLA4 Ab + GM-CSF
BT-001 | Promising Antitumor Activity of OV Armed with Anti-CTLA4 Ab + GM-CSF Completed Phase Click to edit Master I/IIa Trial Assessing IT Route of Administration title style The right virus + payload Promising antitumor activity* monotherapy and combination w. anti-PD1 VVcopTK-RR- oncolytic armed
Slide 16: TG6050 Administered IV | IL-12 and anti-CTLA4 Produced Directly in the Tumor
TG6050 Administered IV | IL-12 and anti-CTLA4 Produced Directly in the Tumor Ongoing Click to edit Phase I Trial Master title style to Assess Systemic Route of Administration Oncolytic armed with IL-12 and anti-CTLA4 Ab • Triggers a powerful antitumor immune response • Restores the immune defenses w
Slide 17: TG4001 | Phase II Trial in Patients with HPV16+ Cervical and Anogenital cancer
TG4001 | Phase II Trial in Patients with HPV16+ Cervical and Anogenital cancer Click to edit Master title style Randomized Phase II trial in patients with HPV16+ cervical Top line data and anogenital cancer (n=90) • Primary objective (improvement in incl. cervical, vulvar, vaginal, penile and anal c
Slide 18: Outlook
Outlook transgene
Slide 19: Company Funded to Deliver Multiple Value Generating Milestones
Company Funded to Deliver Multiple Value Generating Milestones Click to edit Master title style Business funded Enables Transgene to deliver significant milestones with myvac® platform and other until the end of April 2026 viral vector-based immunotherapies | Neoantigen vaccine − TG4050 Other viral
Slide 20: Appendices
Ccremecrane Appendices
Slide 21: New Leadership to Take Transgene to the Next Level
New Leadership to Take Transgene to the Next Level Click to edit Master title style CHRISTOPHE ANCEL, ALESSANDRO RIVA, MD PharmD MAURIZIO CEPPI, PhD Chairman & CEO VP, Chief Quality Officer and VP, Chief Scientific Officer Qualified Pharmacist 30+ years experience EMMANUELLE DOCHY, MD JOHN FELITTI V
Slide 22: TG4050, an Individualized Neoantigen Vaccine Combining Unique Capabilities
TG4050, an Individualized Neoantigen Vaccine Combining Unique Capabilities Combines Bioengineering Click to edit Master title style and Digital Transformation STANDARD DATA PROCESSING, ROUTINE GENE/EXOME ARTIFICIAL GMP TREATMENT TUMOR BIOPSY SEQUENCING INTELLIGENCE GENE EDITING MANUFACTURING ADMINIS
Slide 23: TG4050 | Phase I data − Promising Signals of Clinical Activity in Adjuvant Setting
TG4050 | Phase I data − Promising Signals of Clinical Activity in Adjuvant Setting Click to edit Master title style Head & Neck Cancer Trial 32 patients randomized (R) – As of April 2025 R 6mo. 12mo. 18mo. 24mo. 30mo. 36mo. 42mo. 48mo. 54mo. All 16 treated patients Arm A: remained disease-free TG405
Slide 24: TG4050 | Phase I data − Generates and/or Expands Tumor Specific T Cells
TG4050 | Phase I data − Generates and/or Expands Tumor Specific T Cells Click to edit Master title style Number of positive responses per patient (Elispot assay) Head and Neck Cancer (Phase I part) Despite low mutational burden, De novo responses Amplified responses immunogenic targets could be sele
Slide 25: Exploration of Tumor TME
Exploration of Tumor TME Challenging population with high prevalence of low/negative TME: tumor micro-environment, TMB: tumor mutational burden, PD-L1 expressors and relatively poor pro-immune infiltrates F:Click to edit fibrotic, Master title style NF: non-fibrotic Arm A: TG4050 single agent Arm B:
Slide 26: Environmental, Social and Governance Commitments
Environmental, Social and Governance Commitments Click to edit Master title style 44/100 Vigeo Eiris Transgene’s ESG strategy is based on 6 commitments 85/100 (+20 pts) Gaïa EthiFinance To patients Award (+8 pts) To our partners 99/100 Equal Employment TOP 5 French companies Index To our employees (
Slide 27: Contact
C O N TA C T Lucie Larguier Chief Financial Officer [email protected] 400 Boulevard Gonthier d’Andernach | Parc d’Innovation | CS80166 67405 Illkirch Graffenstaden Cedex | France Tél.: + 33 (0)3 88 27 91 21 | www.transgene.fr 27